Inhibition of mutated, activated BRAF in metastatic melanoma.

@article{Flaherty2010InhibitionOM,
  title={Inhibition of mutated, activated BRAF in metastatic melanoma.},
  author={Keith T. Flaherty and Igor Puzanov and Kevin B. Kim and Antoni Ribas and Grant A. McArthur and Jeffrey A. Sosman and Peter J O'dwyer and Richard J Lee and Joseph F. Grippo and Keith B. Nolop and Paul B. Chapman},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 9},
  pages={
          809-19
        }
}
BACKGROUND The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease. METHODS We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the maximum dose that could be administered without adverse effects (the… 

Figures and Tables from this paper

Inhibition of mutated BRAF in melanoma.
TLDR
Treatment with a BRAF inhibitor was effective for the majority of patients with metastatic melanomas carrying the BRAF V600E mutation and investigation of drugs targeting mutated NRAS might also have therapeutic effects in advanced melanoma.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
TLDR
Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.
Developments in targeted therapy in melanoma.
  • V. Amann, E. Ramelyte, J. Mangana
  • Biology
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2017
Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
The role of BRAF V600 mutation in melanoma
TLDR
The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3) and showed a relative reduction in risk of death and risk of tumor progression.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
TLDR
The structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity, and a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily are described, demonstrating that BRAF-mutant melanomas are highly dependent on B- RAF kinases activity.
BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients
Cutaneous metastatic melanoma management has recently approached the age of individualized therapy (Romano et al., 2011). The discovery that the 1799T>A point mutation in the BRAF oncogene
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
  • Kevin B. Kim, R. Kefford, K. Lewis
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
The response rate for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma, and minimal clinical activity was observed as sequential therapy in patients previously treated with a BRAF inhibitor suggest that BRAf-inhibitor resistance mechanisms likely confer resistance to MEK- inhibitor monotherapy.
BRAF and MEK inhibitors in therapy of advanced melanoma
TLDR
MEK inhibitors didn’t show high efficiency in melanoma therapy, but possibly they will be very helpful in overcoming resistance to BRAF inhibitors, which is quite rapidly occurring resistance to treatment.
BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report
TLDR
The case of a young woman with metastatic melanoma with a particular BRAF mutation, T599I, who has benefited from treatment with a BRAF inhibitor, vemurafenib is described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
TLDR
The data indicate that BRAF gene mutations are a relatively common event in CC but not in HCC, and disruption of the Raf/MEK/ERK (MAPK) kinase pathway was detected in approximately 62% of all CC and is therefore one of the most frequent defects in cholangiocellular carcinogenesis.
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
TLDR
Sorafenib is well tolerated but has little or no antitumour activity in advanced melanoma patients as a single agent at the dose evaluated (400 mg b.i.d.) and there was no relationship between V600E BRAF status and disease stability.
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
TLDR
Testing the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines showed a range of sensitivities to PLX 4032 and metabolic imaging using PET probes can be used to assess sensitivity.
Mutations of the BRAF gene in human cancer
TLDR
BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers, with a single substitution (V599E) accounting for 80%.
A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT.
TLDR
While IM has limited activity in a non-selected melanoma pt population, a substantial proportion of melanomas harboring KIT mut or amp appear to respond and it may be possible to identify appropriate pts prospectively for treatment with IM.
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
TLDR
Results show evidences that BRAF mutations characterize colon but not gastric tumors with MMR deficiency and are not involved in the tumorigenesis of gastric cancer of the mutator phenotype pathway.
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
  • A. Bedikian, M. Millward, F. Haluska
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
The addition of oblimersen to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival in patients without an elevated baseline serum LDH.
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
TLDR
PLX4720, a 7-azaindole derivative that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochemical and cellular assays and represents the entire discovery process from initial identification through structural and biological studies in animal models to a promising therapeutic for testing in cancer patients bearing B- RafV 600E-driven tumors.
BRAF mutations in papillary carcinomas of the thyroid
TLDR
Analysis of mutations of BRAF and RAS genes in 100 cases of thyroid carcinoma suggests that BRAF mutations may play a critical role in the carcinogenesis of papillary carcinoma of the thyroid.
Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
TLDR
A correlation between a gene mutation--BRAF V600E--and cisplatin resistance in nonseminomatous GCTs is reported for the first time and a correlation between MMR deficiency, MSI, and treatment failure is confirmed.
...
1
2
3
4
5
...